Does the switch from Sandimmun to Sandimmun Neoral reduce patient need for Phenihydine?

R. Rosental, I. Adamsone, D. Babarykin, D. Amerika, E. Pettersson

Research output: Contribution to journalArticlepeer-review


In patients receiving cyclosporine A (CyA) - based immunosuppressive therapy, Ca2+ channel blockers (CCBs) prevent the development of CyA - related nephrotoxicity in which increased Ca2+ content plays an important role. We evaluated the dynamics of the intracellular (erythrocytes) and extracellular (plasma) Ca2+ levels and the influence of the CCB, Phenihydine, on this process during the conversion from Sandimmun (S) to Sandimmun Neoral (SN). Forty-two patients were enrolled. The conversion from S to SN normalized the elevated CA2+ level of erythrocytes in groups with Phenihydine (n = 20) and without Phenyhidine (n = 12) 4 weeks after the switch (P < 0.05); this level remained stable until the end of study. Therefore we suggest that the switch from S to SN is effective in reducing elevated intracellular Ca2+ levels. The decrease of Ca2+ content in erythrocytes was similar in all groups switched to SN (with or without Phenihydine). The last effect should be an important argument to focus the further long-term investigations on the ability of CCBs to act as cytoprotective and nephroprotective agents during immunosuppressive protocols with the new microemulsion formulation of CyA.

Original languageEnglish
Pages (from-to)S337-S339
JournalTransplant International
Issue numberSUPPL. 1
Publication statusPublished - 1998


  • Calcium channel blockers
  • CyA formulations
  • Immunosuppression
  • Intracellular calcium
  • Kidney transplantation

Field of Science*

  • 3.1 Basic medicine
  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database


Dive into the research topics of 'Does the switch from Sandimmun to Sandimmun Neoral reduce patient need for Phenihydine?'. Together they form a unique fingerprint.

Cite this